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Non-tuberculous mycobacteria (NTM) frequently colonise patients with end stage cystic fibrosis (CF), but its
impact on the course of the disease following lung transplantation is unknown.
Methods: Lung transplant recipients with CF who underwent lung transplantation at our institution between
January 1990 and May 2003 (n = 146) and CF patients awaiting lung transplantation in May 2003
(n = 31) were studied retrospectively.
Results: The prevalence rate of NTM isolated from respiratory cultures in patients with end stage CF
referred for lung transplantation was 19.7%, compared with a prevalence rate of 13.7% for NTM isolates
in CF lung transplant recipients. The overall prevalence of invasive NTM disease after lung transplantation
was low (3.4%) and was predicted most strongly by pre-transplant NTM isolation (p = 0.001, Fisher’s
exact test, odds ratio (OR) 6.13, 95% CI 3.2 to 11.4). This association was restricted to Mycobacterium
abscessus (p = 0.005, Fisher’s exact test, OR 7.45, 95% CI 2.9 to 16.9). While NTM disease caused
significant morbidity in a small number of patients after transplantation, it was successfully treated and did
not influence the post-transplant course of the disease.
Conclusion: The isolation of NTM before transplantation in CF patients should not be an exclusion criterion
for lung transplantation, but it may alert the clinician to patients at risk of recurrence following
transplantation.
N
on-tuberculous mycobacteria (NTM) are ubiquitous
environmental organisms and are opportunistic
pathogens seen mostly in patients with impaired
systemic immunity or in immunocompetent patients with
chronic airway disease such as chronic obstructive pulmonary
disease or cystic fibrosis (CF). The recognition of NTM as
lung pathogens in immunocompetent hosts is often under-
appreciated as they cause insidious, subtle, and non-specific
symptoms.1 This is especially true in CF patients with severe
bronchiectasis whose airways are chronically infected with
co-existing bacteria that inhibit the in vitro growth of NTM.2–4
A recent large prospective multicentre study that applied
vigilant screening and the use of appropriate NTM culture
techniques showed that NTM are commonly isolated from
the airway secretions of CF patients with an overall
prevalence of 13%.5 Patients with CF develop NTM diseases
restricted to the lung,5–7 whereas patients with advanced
AIDS develop disseminated NTM disease rarely involving the
lung.8 9 This suggests complementary roles for host local lung
defence and systemic immune defence against NTM disease.
NTM infections have increasingly been recognised after
thoracic organ transplantation10–18 with a prevalence of 1.4–
6.5%. Cystic fibrosis is the leading indication for bilateral
lung transplantations, comprising 31.5% and 44% of all adult
and paediatric bilateral lung transplantations worldwide,
respectively.19 A cohort of patients with end stage CF serves
as a unique homogeneous group of high risk lung transplant
candidates in which to study the pre-transplant risk factors
for the development of post-transplant NTM infection/
disease. At the time of transplant surgery the severe
bronchiectatic airways harbouring NTM are removed while
systemic immunosuppressants are introduced. In addition,
CF patients universally receive bilateral lung transplants
which reduces the possibility of seeding NTM from native
tissues.20 CF lung transplant recipients undergo the abrupt
transition from a population with local risk factors for NTM
disease to a population with a combination of risk factors
including altered systemic immune status and inherent
changes in the thorax after surgery.
We have assessed the impact of pre-transplant NTM
infection on the development of post-transplant NTM disease
in a retrospective study.
METHODS
Patient population
All CF patients who underwent lung transplantation at our
institution (UNC) between January 1990 and May 2003
(n = 146) and those awaiting lung transplantation in May
2003 (n = 31) were retrospectively studied. Institutional and
referral medical records, microbiology, radiology and pathol-
ogy databases, and lung transplant files were reviewed in
accordance with the guidelines of the Institutional
Committee on the Protection of the Rights of Human
Subjects. The selection criteria, the operative techniques for
the donors and recipients, and the medical management
following transplantation have been published pre-
viously.11 21 22
Isolation and identification of non-tuberculous
mycobacteria (NTM)
Respiratory specimens from lung transplant candidates,
including sputum and bronchoalveolar lavage (BAL) fluids,
were obtained at UNC from 1993 to May 2003 during routine
Abbreviations: BMI, body mass index; CF, cystic fibrosis; FVC, forced
vital capacity; FEV1, forced expiratory volume in 1 second; NTM, non-
tuberculous mycobacteria* WC and NS contributed equally.
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transplant evaluation or, before that time, from the referral
sites. Respiratory specimens from lung transplant recipients
(including sputum, bronchial wash, BAL fluids, lung tissue
biopsies, and/or pleural fluids) and donors (bronchial washes
immediately after closure) were routinely processed and
examined for the presence of NTM. Protocols for specimen
processing, culture, and identification of NTM have been
described previously.3–5 NTM that were difficult to identify
were sent to the state reference laboratory for identification.
Mycobacterium avium, M intracellulare, and related strains were
cumulatively reported as M avium complex.
NTM isolation and disease definitions
Any positive NTM culture was considered an isolate regard-
less of AFB smear positivity. A negative isolation was defined
as having at least two no-growth culture results. The disease
caused by NTM was diagnosed according to the American
Thoracic Society guidelines23 which include constitutional
symptoms (cough, fever, chills, malaise), radiographic
changes such as new infiltrates, nodules, bacteriological
criteria, positive culture, with or without evidence of
granulomatous inflammation in the lung tissue. The CF
clinicians made the decisions about NTM treatment and
response before transplantation following the best available
literature at that time, and the lung transplant physicians
(usually in consultation with the CF clinicians) managed the
patients after transplantation.
Bronchiolitis obliterans syndrome (BOS) was diagnosed
according to the International Society for Heart and Lung
Transplantation (ISHLT) criteria.24 Pulmonary function test-
ing was performed as previously described.25 After NTM
disease was diagnosed, empirical broad spectrum antibiotics
were initiated based on the speciation according to ATS
guidelines.23 The drug regimen was clarithromycin or
azithromycin, cefoxitin, and amikacin for M abscessus, a
quinolone was substituted for the amikacin in case of renal
toxicity. A regimen of isoniazid, quinolone, rifabutin and
ethambutol was used to treat M kansasii. No significant drug
interactions or adverse events were noted.
Statistical analyses
Non-normally distributed data were presented as medians
and ranges or 95% confidence intervals. Student’s t test was
performed on normally distributed data to determine if there
were any differences in the baseline characteristics of end
stage CF patients who did and did not have NTM isolated
before transplantation. Non-parametric tests were used for
non-normally distributed data. Fisher’s exact test was used to
analyse the association between isolation of NTM before
transplantation and NTM isolation and the development of
NTM disease after transplantation.
RESULTS
Patient population
One hundred and seventy seven lung transplant candidates
with end stage CF constituted the study cohort. Respiratory
specimens were cultured for NTM before transplantation in
132 (75%); for the remaining 45, either the cultures were
overgrown with bacteria, they were insufficient for proces-
sing, or they were not obtained by the referring institution or
UNC. The baseline characteristics of the 132 patients are
shown in table 1. They are representative of the entire
population of 177 CF lung transplant candidates and did not
differ from the 45 patients who did not have NTM cultures
taken before transplantation.
NTM in end stage CF patients
Twenty nine NTM isolates were cultured from the respiratory
specimens of 26 CF lung transplant candidates before
transplantation (prevalence rate 19.7%; fig 1 and table 2).
The characteristics of these 26 NTM positive patients are
compared with those of the 106 NTM negative patients in
table 1. There were no differences in age, sex, forced vital
capacity (%FVC), forced expiratory volume in 1 second
(%FEV1), body mass index (BMI), or the coexistence of
common bacterial pathogens in the CF airway (Pseudomonas
aeruginosa, Burkholderia cepacia complex, or Staphylococcus
aureus) between the two groups (p.0.2 for all).
The most common NTM species isolated was M avium
complex (n = 13, 45%), closely followed by M abscessus
(n = 12, 41%; table 2). Other species recovered included M
gordonae (n = 2, 7%), M fortuitum (n = 1, 3%), and one isolate
was unidentifiable (n = 1, 3%).
Six patients had pre-transplant NTM disease which was
restricted to the lungs (patients 1, 2, 3, 8, 9, and 25 in table 2).
All except one was due to M abscessus. Two patients were
successfully treated, three failed to improve after treatment
(patients 1, 3, and 9), and one was unable to tolerate the side
effects of treatment (patient 2). The symptoms resolved
quickly after treatment, but one of the patients needed long
term treatment due to recrudescence of infection when
antibiotics were withdrawn.
Association between pre-transplant and post-
transplant NTM isolation
None of the lung donors had a past medical history of NTM
infection nor had they cultured NTM. Among pre-transplant
NTM positive patients who underwent transplantation
Table 1 Characteristics of patients with end stage CF
End stage CF patients
from whom an NTM
culture was obtained
(N = 132)
End stage CF patients
with NTM isolates
(N = 26)
End stage CF patients
without NTM isolates
(N = 106) p value*
Age (years) 27.3 (9.1) 28.5 (9.4) 27.1 (9.1) 0.48
Sex (female) 61 (46%) 12 (46%) 49 (45%) 0.92
FVC (l) 1.86 (0.70) 1.98 (0.74) 1.83 (0.69) 0.36
FVC (% ) 46.3 (12.6) 49.1 (14.1) 45.5 (12.0) 0.27
FEV1 (l) 0.92 (0.33) 0.98 (0.32) 0.90 (0.34) 0.29
FEV1 (%) 26.8 (8.8) 28.6 (7.7) 26.4 (9.0) 0.24
BMI (kg/m2) 18.2 (3.0) 18.0 (2.5) 18.2 (3.1) 0.68
Pseudomonas
aeruginosa 100 (76%) 19 (73%) 81 (76%) 0.73
Burkholderia cepacia 25 (19%) 6 (23%) 19 (18%) 0.58
Staphylococcus aureus 68 (51%) 9 (42%) 59 (56%) 0.23
Data are shown as mean (SD) or n (%).
NTM, non-tuberculous mycobacteria; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; BMI, body
mass index.
*End stage CF patients with NTM isolates v end stage CF patients without NTM isolates.
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(n = 18, fig 1; patients 1–18, table 2), seven (39%) cultured
NTM after transplantation. In contrast, NTM was isolated
from 10 of 89 (11%) pre-transplant NTM negative patients
after transplantation, but none developed NTM disease.
There were no differences in any other characteristics
including age, sex, %FVC, %FEV1, BMI, or co-existing
colonisation of Pseudomonas spp or Burkholderia cepacia
complex between pre-transplant NTM positive and NTM
negative transplant recipients (p.0.5 each). Pre-transplant
NTM positive CF patients had 5.03 the odds of culturing NTM
after lung transplantation compared with pre-transplant
NTM negative patients (p = 0.008, table 3). Of seven pre-
transplant NTM positive patients from whom NTM were
isolated after transplantation (patients 1–7, table 2), the
same species was recultured as before transplantation in five
(M abscessus in two (patients 1 and 2), M avium complex in
three (patients 3, 5 and 7), table 2).
NTM isolates in CF lung transplant recipients
One hundred and forty six patients with end stage CF
received double or bilateral lung transplants (fig 1). All lung
transplant recipients routinely had NTM cultures performed
on their respiratory specimens after transplantation at the
time of surveillance or diagnostic bronchoscopy. After a mean
(SD) post-transplant follow up of 47.1 (42.3) months, 20
transplanted recipients cultured 23 isolates of NTM regard-
less of pre-transplant NTM status (prevalence 13.7%; fig 1
and table 2). The NTM were recovered 1–101 months after
transplantation (table 2). The most common species isolated
from transplanted lungs in CF patients were M avium
complex (n = 9, 39%), M gordonae (n = 7, 30%), and M
abscessus (n = 3, 13%), followed by M kansasii (n = 2, 9%); M
szulgai (n = 1, (4%), and M fortuitum (n = 1, 4%; table 2).
There were no differences in pre-transplant characteristics,
including recipient age, %FVC, %FEV1, BMI, or bacterial
colonization in the airway between NTM positive and NTM
negative CF lung transplant recipients (p>0.2 for each
characteristic, table 4). The survival of NTM positive CF
recipients was not significantly different from that of NTM
negative recipients (median 61 (range 11–111), (SD
33.5) months versus 44.7 (SD 39.5) months; p = 0.06).
NTM disease after lung transplantation
With a mean post-transplant follow up of 51.8 (35.6) months
after the first isolate was identified, five of 20 NTM positive
recipients (25%) developed NTM disease (prevalence of 3.4%
among all CF lung transplant recipients, fig 1). Few NTM
species caused disease after lung transplantation (M abscessus
(n = 3) and M szulgai (n = 1), table 2). Only one of 12 M
avium complex isolates that grew concurrent with M szulgai
and one of the two M kansasii caused disease. In contrast,
none of the M gordonae (n = 7) or M fortuitum isolates (n = 1)
caused disease (table 2). Time of disease onset ranged from 3
to 57 months after transplantation (table 2). The clinical and
microbiological features of the patients with post-transplant
NTM disease are summarised in table 2 (n = 5, patients 1, 2,
3, 7, and 39). Overall, the survival of the five CF lung
recipients with post-transplant NTM disease was not
different from that of the 141 without post-transplant NTM
disease (54.9 (27.4) months v 43.1 (37.2) months; p = 0.37).
Association between pre-transplant NTM isolation
and post-transplant NTM disease
Among the pre-transplant NTM positive recipients, four
(22%) developed disease (mean (SD) follow up 34.0
(28.2) months after the first isolate was identified). In
contrast, none of the pre-transplant NTM negative patients
who underwent transplantation (n = 89) developed disease
(fig 1). The odds ratio for pre-transplant NTM positive CF
patients to develop NTM disease after lung transplantation
compared with pre-transplant NTM negative patients was
6.13 (p = 0.001, Fisher’s exact test; table 3). Only pre-
transplant M abscessus positive CF patients were more likely
to develop post-transplant disease when compared with pre-
transplant M abscessus negative patients (odds ratio 7.45;
p = 0.005, Fisher’s exact test; table 3). No significant
association was found between pre-transplant infection and




































































Figure 1 Flow diagram showing the patients with CF included in the study based on the presence of absence of NTM isolation before and after
transplantation.
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Patients who developed NTM disease after lung
transplantation
After NTM disease was diagnosed, empirical antibiotic
regimens were initiated based on the speciation according
to ATS guidelines23 and the clinical details are summarised in
table 5. Full details of these patients are available online at
http://www.thoraxjnl.com/supplemental.
DISCUSSION
NTM were isolated from patients with end stage CF who were
lung transplant candidates and, to a lesser extent, from CF
lung transplant recipients, with prevalence rates of 19.7% and
13.7%, respectively. While post-transplant NTM disease
caused significant morbidity in a small number of patients
(prevalence 3.4%), these patients were successfully treated
and the survival of patients with post-transplant NTM
(isolation or disease) was not different from those without
NTM.
The true prevalence of NTM among end stage CF patients
has not previously been determined; in this study we found
NTM in approximately one in five patients with end stage CF
awaiting lung transplantation. Thus, NTM isolates are more
prevalent among end stage CF patients than among a more
heterogeneous CF population (n = 986) evaluated in a
prospective multicentre study by Olivier et al5 (prevalence
,13%). In both studies the two most common species
isolated from CF airways were M avium complex and M
abscessus.
Table 2 Clinical and microbiological features of patients from whom NTM were isolated before (n = 26) and/or after (n = 20)
transplantation
Sex Age
























1 F 22 M abscessus Sputum ++ 3, 33 M abscessus Wound, blood + 4, 4, 5, 6 0 Yes 90 94
2 M 32 M abscessus Sputum +++ 4, 11 M abscessus Wound swab +++ 3, 4, 4 0 Yes 50 53
3 F 22 MAC Sputum – 12
MAC Sputum, BAL ++ 38, 41 3
Yes 6 44
M szulgai Sputum, BAL ++ 38, 41 3
4 M 29 Unspecified Sputum + 20 M kansasii BAL ++ 8, 10, 10 0 Yes 8 19
5 F 19 MAC Sputum – 14 MAC Sputum, BAL – 69, 69, 69 2 No 28 97
6 F 17 MAC Sputum – 21 M gordonae BAL – 9 0 No 60 69
7 M 25 MAC Sputum – 42
MAC BAL – 18 0 No 24
42
M fortuitum BAL – 11, 13, 18 0 No 31
8 F 20 M abscessus Sputum +++ 1 Negative – – – – – – 28
9 F 26 M abscessus Sputum, BAL +++
Persistent*,
29-7
Negative – – – – – – 3
10 F 31 M abscessus Sputum ++ 5, 6 Negative – – – – – – 23
11 M 19 M abscessus Sputum, BAL
+ 22, 22, 22,
24
Negative – – – – – – 8
12 M 29 M abscessus Sputum ++
Persistent*,
34-2
Negative – – – – – – 21
13 F 27 MAC Sputum – 13 Negative – – – – – – 23
14 F 36 MAC Sputum + 26, 38 Negative – – – – – – 0
15 M 41 MAC Sputum, BAL +++
Persistent*,
41-7
Negative – – – – – – 62
16 F 18 M gordonae Sputum - 31 Negative – – – – – – 19
17 M 32
MAC Sputum N/A 9




MAC Sputum + 34, 36
Negative – – – – – – 62
M fortuitum Sputum – 41
19 M 25 M abscessus Sputum ++ On Tx list – – – – – – – N/A
20 F 14 M abscessus Sputum +++ On Tx list – – – – – – – N/A
21 M 48 M abscessus Sputum +++ On Tx list – – – – – – – N/A
22 M 35 MAC Sputum – On Tx list – – – – – – – N/A
23 M 38 MAC Sputum – On Tx list – – – – – – – N/A
24 M 49 MAC Sputum – On Tx list – – – – – – – N/A
25 F 43
M abscessus Sputum +++
On Tx list – – – – – – – N/A
MAC Sputum –
26 M 33 M gordonae Sputum – On Tx list – – – – – – – N/A
27 F 13 Negative Sputum – – MAC BAL – 4 0 No 25 29
28 F 26 Negative Sputum – – MAC BAL – 35 3 No 4 39
30 M 33 Negative Sputum – – MAC BAL – 18 0 No 54 72
29 M 21 Negative Sputum – – M gordonae BAL – 84 2 No 5 89
31 F 24 Negative Sputum – – M gordonae BAL – 10 0 No 17 27
32 F 29 Negative Sputum – – M gordonae BAL –
Persistent*,
8–31
0 No 51 59
33 M 36 Negative Sputum – – M gordonae BAL – 2 0 No 100 102
34 M 46 Negative Sputum – – M gordonae BAL – 3 0 No 77 80
35 M 29 Negative Sputum – –
MAC BAL – 8, 14 0 No 24
32
M gordonae BAL – 26 0 No 6
36 M 29 Negative Sputum – – M kansasii BAL + 1 0 No 33 34
37 M 31 Unknown N/A N/A N/A MAC Sputum – 117 2 No 7 124
38 F 24 Unknown N/A N/A N/A MAC BAL, wash – 101, 105 3 No 30 135
39 M 27 Unknown N/A N/A N/A M abscessus Sputum, BAL – 57 3 Yes 13 69
*Persistently cultured NTM on .10 occasions.
AFB, acid fast bacilli; MAC, Mycobacterium avium complex; BAL, bronchoalveolar lavage; Tx, transplant.
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Following lung transplantation there have been only four
previous case reports of NTM species isolated from the
airways of CF recipients in the setting of progressive graft
dysfunction. Here we report 20 additional CF lung recipients
with post-transplant pulmonary NTM isolates and confirm
the broad array of clinical settings in which the isolation of
NTM can occur. Moreover, the 13.7% prevalence rate of NTM
isolates among our CF patients after transplant is 2–3 times
higher than in the general (CF and non-CF) lung transplant
population,15 16 indicating that CF patients are particularly
prone to post-transplant NTM infection. We found that the
only pre-transplant predictor for post-transplant NTM isola-
tion or disease was pre-transplant NTM isolation, with pre-
transplant NTM positive patients five times more likely to
culture NTM species and six times more likely to develop
NTM disease after lung transplantation than pre-transplant
NTM negative patients. The similarity of the NTM species
recovered before and after transplantation and the lack of
their recovery from donor lungs in our study suggests that
recurrence of NTM after transplantation was due to
colonisation of the native CF airway above the surgical
anastomoses (main stem bronchi, trachea or sinuses). The
two patients with M abscessus in their explanted (whole) hilar
lymph nodes indicates that other reservoirs of NTM exist
beyond the respiratory tract in patients with CF, and these
may be potential sources of post-transplant infection if
intraoperative contamination occurs.
Pulmonary10–13 15 16 18 and extrapulmonary15–17 diseases
caused by NTM have increasingly been recognised following
thoracic organ transplantation. Without a consensus, the
diagnosis of pulmonary NTM disease and its differentiation
from colonisation in immunocompromised lung transplant
patients represents a significant challenge. Transplant pul-
monologists often treat isolates even if there is uncertainty of
invasive disease. In this study, with a mean follow up of
4 years after recovery of the first isolate, only five of 146 CF
lung recipients (3.4%) developed definite NTM disease, all of
which involved the thorax. However, four of the patients
from whom NTM had been isolated before transplantation
developed NTM disease after surgery (three of whom were
infected with M abscessus). Only one patient (,1%) developed
disseminated disease. Thus, NTM isolation after transplanta-
tion in individuals with CF is common, but rates of invasive
disease are low.
Four cases of M abscessus disease have been reported in
general lung transplant recipients manifesting as empyema
with (n = 1) or without (n = 2)15 18 mycobacteraemia or graft
dysfunction (n = 1),13 resulting in death due to ventilatory
failure.18 26 We extended these findings by confirming the
particular virulence of M abscessus and its ability to recur after
transplantation. Pre-transplant M abscessus culture positive CF
patients, regardless of AFB smear positivity, were more likely
to develop post-transplant disease than pre-transplant M
abscessus culture negative patients. Thus, a recurrent isolation
of M abscessus from a CF lung transplant recipient should
increase the suspicion of the development of disease until
proved otherwise. In addition, we observed two distinct
presentations by M abscessus after lung transplantation: early
infections that caused empyema or mediastinitis, and late
infection in the setting of severe lung graft dysfunction (BOS









Odds ratio p value
Post-transplant NTM infection
(n = 17)
7 (38.9%) 10 (12.2%) 5.03 0.003*
Post-transplant NTM disease
(n = 4)
4 (22.2%) 0 (0%) 6.13 0.001*
No post-transplant NTM
infection or disease (n = 86)








disease (n = 4)
2 (28.6%) 0 (0%) 7.45 0.005*
*Fisher’s exact test.
Among those who had NTM cultures pre-transplant.








(N = 126) p value
Age at transplant (years) 26.7 (7.3) 26.5 (8.5) 0.9
Sex (female) 8 (40%) 61 (48%) 0.65
FVC (l) 1.97 (0.70) 1.68 (0.64) 0.09
FVC (%) 45.7 (15.5) 43.2 (12.1) 0.52
FEV1 (l) 0.94 (0.3) 0.84 (0.3) 0.20
FEV1 (%) 25.6 (7.5) 25.2 (8.7) 0.80
BMI (kg/m2) 17.4 (2.3) 17.7 (2.5) 0.70
Pseudomonas aeruginosa 12 (60%) 88 (69%) 0.54
Burkholderia cepacia 5 (25%) 25 (20%) 0.35
Staphylococcus aureus 6 (30%) 53 (42%) 0.44
Data are shown as mean (SD) or n (%).
NTM, non-tuberculous mycobacteria; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; BMI,
body mass index.
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stage 3) that caused lung abscess. In contrast to a previous
report, we did not find that M avium complex was a common
cause of post-transplant NTM disease.15 In the only case of
disease associated with M avium complex in our study, co-
infection with M szulgai, a known human pathogen,27 may
have been exclusively responsible for her deterioration.
These data suggest that the high rate of NTM isolation in
CF patients before transplantation results in higher rates of
NTM isolation after transplantation but, with the exception
of M abscessus, does not increase the rate of NTM disease.
While treatment can be challenging, all three cases of M
abscessus disease and the one case of M kansasii disease were
successfully treated. As a result, the survival of patients with
post-transplant NTM isolation or disease was not different
from those without. Proactive pre-transplant surveillance for
NTM is advocated; the possible benefits from additional
intraoperative NTM specific antiseptic practices for these
recipients remain unsettled.
This study has potential shortcomings. Retrospective
studies can be limited by ascertainment bias, despite our
best efforts to review all available paper and electronic
records. In addition, we relied on microbiology results over a
long time period, so protocols for specimen processing,
culture, and identification of NTM may have varied leading
us to underestimate the number of cases of isolation and
disease. Thirdly, considerable controversy exists over the
definitions of isolation, colonisation, infection, and disease
which makes it difficult to extrapolate from the non-CF
literature and might confound our prevalence statistics.
Nonetheless, this is the largest study of NTM in CF patients
referred for and following lung transplantation, and our
lengthy follow up without the development of disease in
cases we defined as ‘‘NTM isolation’’ strengthened our
conclusions. Fourthly, as this was a single centre study it
was limited by a relatively small number of NTM disease
cases and changes in practice over time may have affected the
overall results. Lastly, we did not perform molecular
genotyping studies to confirm that the cases of M abscessus
that occurred early after transplantation were true
recurrences rather than new acquisitions. Further study of
NTM in patients with CF will be required before treatment
recommendations can be made to address NTM positive
patients before referral for lung transplantation. In addition,
comprehensive studies to assess potential post-transplant
risk factors for NTM in both CF and non-CF patients are
needed.
In conclusion, NTM are very commonly isolated from the
airways of end stage CF lung transplant candidates. CF
recipients are at increased risk for NTM isolation and NTM
disease after lung transplantation. However, the overall rates
of invasive disease are low and the increased risk for post-
transplant NTM disease is restricted largely to those with pre-
transplant M abscessus isolates. Medical treatment effectively
controls NTM disease after lung transplantation, resulting in
no attributable mortality. The isolation of M abscessus before
transplantation was associated with post-transplant disease
and morbidity but did not affect survival. We recommend
proactive transplant surveillance for patients with M abscessus
isolates, and we await an outcomes analysis from other
centres to confirm our findings and help us to understand
better the full impact of M abscessus on post-transplant
survival. Our findings support the view that isolation of M
abscessus from the sputum should be considered a relative but
not an absolute contraindication for transplantation.
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Table 5 Clinical presentation and outcome of patients with post-transplant NTM disease
Patient Diagnosis NTM Sensitivities Treatment Duration Outcome
1 Sternal wound abscess/
mediastinitis






48 months Died 10 years after
transplant from multiple
problems
2 Sternal wound abscess/
empyema





27 months Normal graft function at
follow up
3 New pulmonary infiltrates MAC Not obtained Refused treatment as
had severe BOS
Died





2 months Normal graft function at
follow up
39 Lung abscess and
mediastinal
lymphadenapathy





11 months Died of disseminated
mucomycosis
NTM, non-tuberculous mycobacteria; BOS, bronchiolitis obliterans syndrome; MAC, Mycobacterium avium complex.
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